国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (8): 699-702.doi: 10.3760/cma.j.issn.1673422X.2016.09.015

• 综述 • 上一篇    下一篇

乳腺癌PIK3CA基因突变与抗HER2靶向治疗疗效的相关性

邵喜英, 郑亚兵, 王晓稼   

  1. 310022  杭州，浙江省肿瘤医院乳腺肿瘤内科
  • 出版日期:2016-09-08 发布日期:2016-08-04
  • 通讯作者: 王晓稼，Email: wxiaojia0803@163.com E-mail:wxiaojia0803@163.com
  • 基金资助:

    浙江省自然科学基金(Y2101312)；浙江省重大科技专项(2012C130191)；浙江省医药卫生科技计划(2016KYA046、2016RCA003、2015RCB005、2010QNA006)；浙江省医药卫生省部培育计划(2015PYA001)

Shao Xiying, Zheng Yabing, Wang Xiaojia   

  1. Medical Oncology of Breast Cancer, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2016-09-08 Published:2016-08-04
  • Contact: Wang Xiaojia E-mail:wxiaojia0803@163.com
  • Supported by:

    Natural Science Foundation of Zhejiang Provincial of China (Y2101312); Science and Technology Department of Zhejiang Province of China (2012C130191); Zhejiang Provincial Medical Science and Technology Program (2016KYA046, 2016RCA003, 2015RCB005, 2010QNA006); Cultivation Plan for the Ministry of Medicine and Health of Zhejiang Province of China (2015PYA001)

PDF

1212

摘要： HER2阳性乳腺癌PIK3CA 基因突变率高达25%，该基因突变能激活PI3KAkt信号通路并促进HER2介导的肿瘤细胞上皮转化，改变HER2过表达肿瘤的内在表型，进而导致抗HER2靶向治疗耐药。相关研究发现，PIK3CA基因突变与抗HER2靶向治疗疗效相关。因此，实时监测PIK3CA 基因突变状态将有助于实现个体化抗HER2靶向治疗。

关键词: 乳腺肿瘤, 受体, 表皮生长因子, PIK3CA基因突变

Abstract: The correlation of PIK3CA gene mutation and the efficacy of antiHER2 targeted therapy for breast cancer

Key words: Breast neoplasms, Receptor, epidermal growth factor, PIK3CA gene mutation